College of American Pathologists Conference XXXV: solid tumor prognostic factors-which, how and so what? Summary document and recommendations for implementation. Cancer Committee and Conference Participants.
College of American Pathologists Conference XXXV: solid tumor prognostic factors-which, how and so what? Summary document and recommendations for implementation. Cancer Committee and Conference Participants.
复制标题
DOI：
10.1043/0003-9985(2000)124
复制
发表时间：
2000-08
影响因子：
4.6
通讯作者：
M. Hammond;P. Fitzgibbons;C. Compton;D. Grignon;D. Page;L. Fielding;D. Bostwick;T. Pajak
中科院分区：
文献类型：
--
作者：
M. Hammond;P. Fitzgibbons;C. Compton;D. Grignon;D. Page;L. Fielding;D. Bostwick;T. Pajak
美国病理学家学会于1999年6月召开了一次预后因素会议，讨论乳腺癌、结肠癌和前列腺癌的预后和预测因素，并将这些因素分为反映已发表证据强度的类别。由于在过去的5年中，预后因素的临床应用进展甚微，与会者将注意力集中在减少这些因素的方法、解释和报告的变化上，以便更清楚地了解其价值。组织这次会议是为了促进讨论、广泛投入和未来规划。第一次全体会议概述了肿瘤标志物研究的现状，医学和病理学变化的影响，以及与预后因素研究相关的统计问题。在每种癌症类型的工作组会议中，参与者交互式地评估和完善专家小组创建的文件。第二次全体会议讨论了所有3组共同的问题，包括这些部位淋巴结微转移的问题;分组讨论中出现的统计问题;以及免疫组化检测方法、解释和报告的变化问题。一个教师会议集思广益的战略，可用于实施建议的变化。本次会议邀请了美国食品和药物管理局、医疗保健融资管理局、疾病控制和预防中心、国家癌症研究所、美国癌症联合委员会和国际抗癌联盟的代表。在最后一次会议上提出并讨论了癌症部位和一般性建议，以使与会者达成共识，并讨论实施这些建议的可行性。最后讨论的重点是可能导致实施与会各组织在会议上提出的改革的未来倡议。本报告总结了大会的建议、癌症工作组的建议以及实施这些建议的计划。
The College of American Pathologists convened a prognostic factor conference in June 1999 to consider prognostic and predictive factors in breast, colon, and prostate cancer, and to stratify these factors into categories reflecting the strength of published evidence. Because so little progress in prognostic factor clinical utility has been made in the last 5 years, the conference participants focused their attention on decreasing variation in methods, interpretation, and reporting of these factors so that greater clarity of value could be achieved. The conference was organized to promote discussion, broad input, and future planning. An initial plenary session provided an overview of the status of tumor marker research, the impact of variation in medicine and pathology, and statistical issues related to prognostic factor research. In working group sessions for each cancer type, participants interactively evaluated and refined the documents created by the expert panels. A second plenary session dealt with issues common to all 3 groups, including the problem of micrometastases in lymph nodes in these sites; statistical issues that arose during the breakout discussions; and issues of variation in methods, interpretation, and reporting of immunohistochemical assays. A faculty session brainstormed strategies that could be used to implement the changes recommended. This session included invited representatives of the Food and Drug Administration, Health Care Financing Administration, Centers for Disease Control and Prevention, National Cancer Institute, American Joint Committee on Cancer, and International Union Against Cancer. Cancer site and general recommendations were presented and discussed during a final session to achieve consensus of the conference participants and to address feasibility of implementation of these recommendations. A final discussion focused on future initiatives that might lead to implementation of the changes proposed in the conference by the various organizations represented. This report summarizes the general conference recommendations, cancer working group recommendations, and plans for implementation of the recommendations.